WuXi Biologics Wins Multiple Awards at the APBCEA 2025 Ceremony for CDMO Excellence
WuXi Biologics, a prominent Contract Research, Development and Manufacturing Organization (CRDMO), recently achieved significant recognition at the Asia Pacific Biologics CDMO Excellence Awards (APBCEA) 2025 held in Singapore. The company was awarded the titles of "CDMO of the Year – Asia Pacific," "Best Biologics CDMO Award Bioprocessing," and "Best Biologics CDMO in the Greater China Region." These awards highlight WuXi Biologics' commitment to innovation and excellence in the biomanufacturing sector, underscoring its role in accelerating biologics innovation across the Asia Pacific region.
Since its inception in 2017, WuXi Biologics has consistently received accolades at IMAPAC's industry events, indicating its growing influence and reputation. The APBCEA aims to celebrate leading CMOs that drive biologics innovation and improve the development and commercialization of new biologic therapies. Recognized for cutting-edge research, development, technological innovation, and strategic partnerships, WuXi Biologics stands at the forefront of the biologics field.
One of the key strengths of WuXi Biologics is its robust, integrated technology platforms aimed at speeding up the discovery, development, and manufacturing processes of biologics. The company has cultivated one of the industry's largest portfolios, managing a total of 864 integrated projects. Among these, it boasts a diverse array of complex biologics, including 168 bispecific and multispecific antibodies along with 225 Antibody-Drug Conjugates (ADCs). The efficient development cycle for monoclonal antibody projects, now shortened to just six months from DNA to Investigational New Drug application, exemplifies the company's capacity for flexibility and speed in meeting client needs.
These achievements are made possible by WuXi Biologics' commitment to maintaining world-class quality systems. The company has achieved a 100% success rate in Pre-License Inspections (PLI) and has successfully cleared 44 inspections from global regulatory authorities, including 22 by the FDA and EMA. With this emphasis on quality assurance, WuXi Biologics can offer comprehensive end-to-end services to over 1,000 clients worldwide, assisting in bringing their biologics products from concept to market.
Dr. Chris Chen, CEO of WuXi Biologics, expressed pride in receiving these awards, stating, "We are very pleased that WuXi Biologics has once again won multiple awards presented by IMAPAC, which fully demonstrates the recognition we have earned from both clients and the industry for the value we consistently deliver. We remain steadfast in empowering our partners to accelerate groundbreaking therapies to patients worldwide at an earlier date."
The company employs over 12,000 skilled workers across its facilities in China, the United States, Ireland, Germany, and Singapore, leveraging their expertise and technological advancements to provide efficient and cost-effective solutions for biologics. As of June 30, 2025, WuXi Biologics supports 864 projects, with 24 currently undergoing commercial manufacturing.
Additionally, WuXi Biologics is deeply committed to sustainability, underscoring the importance of green technology innovations for long-term business success. The company's goal is to offer progressive end-to-end Green CRDMO solutions that align with industry standards. By collaborating with all stakeholders, WuXi Biologics aims to cultivate positive social and environmental impacts while promoting responsible practices throughout the value chain.
For more details on WuXi Biologics and their pioneering efforts in the field of biologics, please visit their official website at www.wuxibiologics.com.
Since its inception in 2017, WuXi Biologics has consistently received accolades at IMAPAC's industry events, indicating its growing influence and reputation. The APBCEA aims to celebrate leading CMOs that drive biologics innovation and improve the development and commercialization of new biologic therapies. Recognized for cutting-edge research, development, technological innovation, and strategic partnerships, WuXi Biologics stands at the forefront of the biologics field.
One of the key strengths of WuXi Biologics is its robust, integrated technology platforms aimed at speeding up the discovery, development, and manufacturing processes of biologics. The company has cultivated one of the industry's largest portfolios, managing a total of 864 integrated projects. Among these, it boasts a diverse array of complex biologics, including 168 bispecific and multispecific antibodies along with 225 Antibody-Drug Conjugates (ADCs). The efficient development cycle for monoclonal antibody projects, now shortened to just six months from DNA to Investigational New Drug application, exemplifies the company's capacity for flexibility and speed in meeting client needs.
These achievements are made possible by WuXi Biologics' commitment to maintaining world-class quality systems. The company has achieved a 100% success rate in Pre-License Inspections (PLI) and has successfully cleared 44 inspections from global regulatory authorities, including 22 by the FDA and EMA. With this emphasis on quality assurance, WuXi Biologics can offer comprehensive end-to-end services to over 1,000 clients worldwide, assisting in bringing their biologics products from concept to market.
Dr. Chris Chen, CEO of WuXi Biologics, expressed pride in receiving these awards, stating, "We are very pleased that WuXi Biologics has once again won multiple awards presented by IMAPAC, which fully demonstrates the recognition we have earned from both clients and the industry for the value we consistently deliver. We remain steadfast in empowering our partners to accelerate groundbreaking therapies to patients worldwide at an earlier date."
The company employs over 12,000 skilled workers across its facilities in China, the United States, Ireland, Germany, and Singapore, leveraging their expertise and technological advancements to provide efficient and cost-effective solutions for biologics. As of June 30, 2025, WuXi Biologics supports 864 projects, with 24 currently undergoing commercial manufacturing.
Additionally, WuXi Biologics is deeply committed to sustainability, underscoring the importance of green technology innovations for long-term business success. The company's goal is to offer progressive end-to-end Green CRDMO solutions that align with industry standards. By collaborating with all stakeholders, WuXi Biologics aims to cultivate positive social and environmental impacts while promoting responsible practices throughout the value chain.
For more details on WuXi Biologics and their pioneering efforts in the field of biologics, please visit their official website at www.wuxibiologics.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.